Stem Cell Therapy

Arm 1 for Stargardt Disease

Fakeeh University Hospital, Dubai, United Arab Emirates
Targeting 19 different conditionsArm 1N/ARecruitingLed by Jeffrey Weiss, MDResearch Sponsored by MD Stem Cells

Study Summary

This trial will test whether injecting stem cells derived from a patient's own bone marrow can help treat damage to the retina or optic nerve.

Eligible Conditions
  • Stargardt Disease
  • Retinal Disease
  • Blindness
  • Optic Atrophy
  • Low Vision
  • Optic Neuropathy
  • Ischemic Optic Neuropathy
  • Leber Optic Neuropathy
  • Night Blindness
  • Partial Vision Loss
  • Macular Abnormality
  • Retinal Atrophy
  • Retinal Disorders
  • Retinitis Pigmentosa
  • Age-Related Macular Degeneration
  • Glaucoma

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
Your condition can benefit from BMSC treatment and the procedure poses little risk to your health.
You have a good chance of benefiting from the BMSC treatment and there is very little risk of harm from the procedure.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from pre-procedure to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from pre-procedure to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Visual Acuity
Secondary outcome measures
Optical Coherence Tomography (OCT)
Visual Fields

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Arm 1Experimental Treatment1 Intervention
BMSC provided retrobulbar, subtenon and intravenous for one or both eyes
First Studied
Drug Approval Stage
How many patients have taken this drug
Arm 1

Find a site

Who is running the clinical trial?

MD Stem CellsLead Sponsor
4 Previous Clinical Trials
940 Total Patients Enrolled
Steven Levy, MDStudy Chair
MD Stem Cells
4 Previous Clinical Trials
940 Total Patients Enrolled
Jeffrey Weiss, MDPrincipal Investigator
Coral Springs
4 Previous Clinical Trials
940 Total Patients Enrolled

Media Library

Arm 1 (Stem Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03011541 — N/A
Stargardt Disease Research Study Groups: Arm 1
Stargardt Disease Clinical Trial 2023: Arm 1 Highlights & Side Effects. Trial Name: NCT03011541 — N/A
Arm 1 (Stem Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03011541 — N/A
Stargardt Disease Patient Testimony for trial: Trial Name: NCT03011541 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this examination currently enrolling participants?

"Per the listing, recruitment is still open for this experiment that was initially posted on January 1st 2016 and revised lastly in November 25th 2022."

Answered by AI

To what extent is participation in this medical experiment limited?

"Affirmative. According to the information published on, this medical trial is currently recruiting participants and was initially posted on New Year's Day 2016 before being updated in November 2022. The research team are hoping to enrol 500 patients from two different sites."

Answered by AI

Who else is applying?

What state do they live in?
New York
How old are they?
18 - 65
What site did they apply to?
Medcare Orthopaedics & Spine Hospital
MD Stem Cells
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?

Why did patients apply to this trial?

I have low T, 295. diagnosed with Retinitis pigmentosa. I feel like I can put my trust in them.
I am night blind and only 28 years old. Please help. I’ll try anything at this point.

What questions have other patients asked about this trial?

How long do the screening process take and when can I start?

How responsive is this trial?

Typically responds via
Phone Call
Most responsive sites:
  1. MD Stem Cells: < 24 hours
  2. Medcare Orthopaedics & Spine Hospital: < 24 hours
Average response time
  • < 2 Days
Recent research and studies
~44 spots leftby Jul 2024